Clinical trial of Muse cell therapy has started as below.
These clinical trials are conducted by Life Science Institute Inc., the group company of Mitsubishi Chemical holdings.
Re: Business Operations of SanBio Co., Ltd.
Recently, we received multiple inquiries about SanBio Co., Ltd.
(Tokyo, Japan; hereinafter, "SanBio"), presumably based on a misunderstanding of the relationship between certain projects undertaken by this corporation and the Muse cell research that our laboratory promotes under the leadership of Prof. Mari Dezawa. Dr. Dezawa had been one of the founding scientists of SanBio, Inc. (CA, U.S.A.), a subsidiary of SanBio, but resigned in April 2010. Since then, Dr. Dezawa has dissolved the relationship with both SanBio, Inc. and SanBio. Dr. Dezawa and our laboratory are no longer involved in the development of SB623 cells or other SanBio projects. Therefore, neither Dr. Dezawa nor other members of our laboratory are responsible for any of SanBio's activities, products, or other business operations.
We wish to emphasize that Muse cells are totally different from, and have nothing to do with, the cells that SanBio and SanBio, Inc. developed. Life Science Institute, Inc. (Tokyo, Japan) is exclusively responsible for the commercialization and other business operations related to Muse cells.
This book presents up-to-date knowledge on Muse cells, newly recognized pluripotent stem cells that will be vital for next-generation medical care.
*Election to NAI Fellow status is the highest professional distinction accorded solely to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.